Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > Comparisons of single agents

<< Previous

Bullboard Posts

Next >>

Post by enriquesuaveon Apr 05, 2022 11:38am

250 Views

Post# 34576843

Comparisons of single agents

90 days 12 months # of treatments in 12 months period

Keytruda. 41%. 19%. 18. IV

Vicinium. 42%. 17%. 36

Adstiladrin. 50%. 24%. 4

TLD-1433. 50%. 25%. 2. Non optimized evaluable patients

TLD-1433. 60%. 11.1%. 2. Too early to assess not enough data

Data is beating all single agents and potential for PR patients to convert to CR status increases the potential to beat present data.